Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/120590
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Domínguez García, Àngela | - |
dc.contributor.author | Soldevila, Núria | - |
dc.contributor.author | Toledo Zavaleta, Diana Isabel | - |
dc.contributor.author | Torner Gràcia, Núria | - |
dc.contributor.author | Force, Lluís | - |
dc.contributor.author | Pérez Lozano, María José | - |
dc.contributor.author | Martín Sánchez, Vicente | - |
dc.contributor.author | Rodríguez Rojas, Lourdes | - |
dc.contributor.author | Astray, Jenaro | - |
dc.contributor.author | Egurrola, Mikel | - |
dc.contributor.author | Sanz, Francisco | - |
dc.contributor.author | Castilla, Jesús | - |
dc.date.accessioned | 2018-03-09T11:41:02Z | - |
dc.date.available | 2018-03-09T11:41:02Z | - |
dc.date.issued | 2017-02-10 | - |
dc.identifier.issn | 1932-6203 | - |
dc.identifier.uri | http://hdl.handle.net/2445/120590 | - |
dc.description.abstract | Pneumococcal pneumonia is a serious cause of morbidity and mortality in the elderly, but investigation of the etiological agent of community-acquired pneumonia (CAP) is not possible in most hospitalized patients. The aim of this study was to estimate the effect of pneumococcal polysaccharide vaccination (PPSV23) in preventing CAP hospitalization and reducing the risk of intensive care unit admission (ICU) and fatal outcomes in hospitalized people aged 65 years. We made a multicenter case-control study in 20 Spanish hospitals during 2013-2014 and 2014-2015. We selected patients aged 65 years hospitalized with a diagnosis of pneumonia and controls matched by sex, age and date of hospitalization. Multivariate analysis was performed using conditional logistic regression to estimate vaccine effectiveness and unconditional logistic regression to evaluate the reduction in the risk of severe and fatal outcomes. 1895 cases and 1895 controls were included; 13.7% of cases and 14.4% of controls had received PPSV23 in the last five years. The effectiveness of PPSV23 in preventing CAP hospitalization was 15.2% (95% CI -3.1-30.3). The benefit of PPSV23 in avoiding ICU admission or death was 28.1% (95% CI -14.3-56.9) in all patients, 30.9% (95% CI -32.2-67.4) in immunocompetent patients and 26.9% (95% CI -38.6-64.8) in immunocompromised patients. In conclusion, PPSV23 showed a modest trend to avoidance of hospitalizations due to CAP and to the prevention of death or ICU admission in elderly patients hospitalized with a diagnosis of CAP. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Public Library of Science (PLoS) | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0171943 | - |
dc.relation.ispartof | PLoS One, 2017, vol. 12, num. 2, p. e0171943 | - |
dc.relation.uri | https://doi.org/10.1371/journal.pone.0171943 | - |
dc.rights | cc-by (c) Domínguez García, Àngela et al., 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Vacunes | - |
dc.subject.classification | Pneumònia | - |
dc.subject.classification | Polisacàrids | - |
dc.subject.classification | Persones grans | - |
dc.subject.other | Vaccines | - |
dc.subject.other | Pneumonia | - |
dc.subject.other | Polysaccharides | - |
dc.subject.other | Older people | - |
dc.title | Effectiveness of 23-valent pneumococcal polysaccharide vaccination in preventing community-acquired pneumonia hospitalization and severe outcomes in the elderly in Spain | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 670662 | - |
dc.date.updated | 2018-03-09T11:41:02Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 28187206 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
670662.pdf | 820.93 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License